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Chromaffin cells from bovine adrenal medulla are a useful model to approach adenosine transport and me- 
tabolism in neural cells. Dipyridamol has been shown to be an adenosine transport inhibitor with high affin- 
ity. To quantify the adenosine transporters a labelled dipyridamol analogue, [r4C]dipyridamol acetate, was 
synthesized. This compound had a K, = 5.3 + 0.43 nM according to the Dixon method, and 4.58 + 0.46 
nM when the receptor number molarity was taken into account showing, like dipyridamol, a non-competi- 
tive mechanism. The high-affinity receptors present in chromaffin cells showed a I& = 6.8 _+ 0.8 nM and 
the receptor number was 630000 + 40000 per cell. 
Adenosine transport Chromafin cell Dipyridamol 
1. INTRODUCTION 
Chromaffin cells from bovine adrenal medulla 
are a useful model to approach basic neural 
problems [l-6]. Due to both the increasing im- 
portance of adenosine as a neural modulator [7,8] 
and the necessary purine ring recovery when ATP 
is released by exocytosis from these cells the 
transport, incorporation and metabolism of 
adenosine have been recently studied in this tissue 
[9-111. Only one high-affinity adenosine 
transporter has been shown in recently isolated or 
cultured chromaffin cells; dipyridamol being a 
non-competitive transport inhibitor in the nM 
range [ 121. This compound has been used exten- 
sively for clinical purposes and has also been 
shown to be a good inhibitor in other neural and 
non-neural cells [13,14]. The present possibility of 
quantifying adenosine transporters could prove to 
be the first step in studying the effects of hormonal 
or neural factors on subcellular distribution and its 
regulation, as is the case with glucose transporters 
+ To whom correspondence should be addressed 
[ 15,161. Thus, a dipyridamol analogue, dipyrida- 
mol monoacetate, was synthesized, studied for its 
inhibitory capacity and, as a’labelled derivative, 
used for binding in order to quantify the adenosine 
transporters in recently isolated chromaffin cells. 
2. MATERIALS AND METHODS 
2.1. Materials 
Collagenase (EC 3.4.24.3), Dulbecco’s modified 
Eagle’s medium and dipyridamol were purchased 
from Sigma; Percoll from Pharmacia; [2,5’,8- 
3H]adenosine (45 Ci/mmol) from Amersham; 
[l-14C]acetyl chloride (55 mCi/mmol) from New 
England Nuclear. Silicex 342 and silicex 334 were 
from Siliconas Hispania S.A. 
2.2. Synthesis of dipyridamol monoacetate 
Dipyridamol was acetylated at one of the 
alcohol functions using acetyl chloride in a 1: 1 
molar ratio. Both substances were dissolved in 
water-free chloroform, the mixture was then stir- 
red at room temperture for 2 h and at the end of 
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the reaction, HCI and chloroform were eliminated 
by evaporation. 
Infrared spectra were obtained in Nujol emul- 
sion and analyzed in a Nicolet FT-SDX. 
equilibrium being reached after 15 min. The cells 
were then centrifuged over 300 pl silicone oil mix- 
ture as described, and the bound form (pellet) and 
free form (supernatant) were counted. 
When labelled derivative was necessary, 
[l-14C]acetyl chloride (55 mCi/mmol) was used in 
the same reaction conditions. 
The mass spectrum was recorded using a 
Hewlett-Packard 59993 GC/MS system. Thin 
layer chromatography was carried out in alumina 
precoated plastic sheets with benzene/ethanol 1: 1 
(by vol.). 
All values in the text are given as means f SD. 
Linear regression equations were calculated by the 
least-squares method using an Olivetti M-20 com- 
puter with a linear regression program. 
3. RESULTS 
3.1. Synthesis of dipyridamol monoacetate 
2.3. Isolation of chromaffin cells 
Chromaffin cells were isolated from bovine 
adrenal glands essentially according to Miras- 
Portugal et al. [9]. The cells were isolated by col- 
lagenase action and purified through a Percoll gra- 
dient, carefully collected and washed with Ca*+, 
Mg*+ free Locke’s solution. Finally, all cells were 
suspended in Dulbecco’s modified Eagle’s medium 
(DMEM). Only preparations with a cellular viabili- 
ty over 90% were employed. 
In fig. 1, infrared spectra of dipyridamol (A) and 
its acetate derivative (B) are shown. A 
characteristic acetate band can be observed at 
1740 cm-‘, the free hydroxyl groups having 
2.4. Adenosine transport studies 
Recently isolated chromaffin cells were always 
maintained in DMEM for at least 2 h before any 
experiment was performed, in order for the mem- 
branes to be restored; this being considered 
necessary due to other proteases present in com- 
mercial collagenases . 
Assays of adenosine transport were carried out 
by the method of Paterson and co-workers [17] 
and modified by Miras-Portugal et al. as described 
[12]. Essentially, 2 x lo6 cells were incubated in 
200~1 DMEM with [2,5’,8-3H]adenosine (1 ,&i) 
and non-labelled adenosine at the required final 
concentration. Transport was stopped at the in- 
dicated times by the addition of 5 pM dipyridamol, 
the cells were immediately layered over a silicone 
oil mixture (200 ~1, d = 1.04) and centrifuged at 
10000 x g in a Beckman microfuge. Cells were 
pelleted at the end of the tube, resuspended in 
Triton X-100 (1070) and their radioactivity counted. 
2.5. Binding assay 
Binding experiments with [14C]dipyridamol rrg.1. 
monoacetate (55 mCi/mmol) were carried out with 
Infrared spectra of dipyridamol (A) and 
4 x lo6 cells in a final volume of 1 ml. The ligand 
dipyridamol monoacetate (B). Infrared spectra were 
obtained in Nujol emulsion and analyzed in a Nicolet 
concentration ranged from 1.14 to 114 nM; F’T-SDX. 
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diminished. The mass spectrum (EI) confirmed the 
monoacetylated erivative by the presence of an 
expected molecular ion peak at m/z 546. The puri- 
ty of the compound was checked by thin layer 
chromatography, only one molecular form being 
observed. 
3.2. Dipyridamol monoacetate inhibition of 
adenosine transport 
Dipyridamol monoacetate is a good inhibitor of 
adenosine transport, as shown in fig.2, its effects 
being greater than those obtained by the same 
dipyridamol concentration. Adenosine transport 
was measured at short periods of time (5-60 s) 
because, at these times, no significant synthesis of 
adenine nucleotides from external adenosine took 
place in these cells [12]. The high affinity of 
dipyridamol acetate for adenosine transporters is 
shown in fig.3, where a classical Dixon plot can be 
seen; the Ki obtained was 5.3 + 0.43 nM, showing 
a non-competitive mechanism at the adenosine 
transport level. The Ki value was also determined 
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Fig.2. Effect of dipyridamol and dipyridamol mono- 
acetate on adenosine transport by recently isolated 
chromaffin cells. 2 x lo6 cells were incubated in the 
absence (0) or presence of 10 nM dipyridamol (A) and 
10 nM dipyridamol monoacetate ( n ) in a final volume of 
2004 DMEM for 5 min. Adenosine transport was 
measured by adding 0.1 pM [2,5 ’ ,8-3H]adenosine (1 &i 
essay). T represents the adenosine transport expressed in 
pmol/lO” cells. The data points are means (k SD) of 3 
experiments in triplicate. 
Fig.3. Dixon plots of dipyridamol monoacetate 
inhibitory effect on adenosine transport by recently 
isolated chromaffin cells. As before, cells were 
preincubated with variable concentrations of dipyrida- 
mol monoacetate for 5 min. 1 &i [2,5 ’ ,8-3H]adenosine 
and non-labelled adenosine were then added to reach 
0.1 pM (o), 0.5 /IM (A) and 1 PM (m), this being the 
final concentration. T represents the adenosine transport 
measured over a linear range period and expressed in 
pmol/106 cells per min. [Ij represents the nM concentra- 
tion of dipyridamol monoacetate. This figure is typical 
of results obtained from 3 different experiments in 
triplicate, the correlation coefficients being r = 0.999 for 
0.1 pM adenosine, r = 0.996 for 0.5 PM adenosine, and 
r = 0.985 for 1 PM adenosine. 
taking into account the total transporter number 
(AdoTT) obtained from fig.4 and resolving the 
Henderson equation [18] for reversible non- 
competitive inhibitors with high affinity, 
[IT]/[ 1 - (ti/to)] = Ki(tJti) + (AdoTr), to and ti be- 
ing the transport values from fig.2. The Ki ob- 
tained was 4.58 + 0.46 nM, without significant 
changes during a 20-60 s period, once transport 
had started. 
3.3. Adenosine transporter quantification 
Adenosine transporter quantification was ac- 
complished by the labelled ligand technique, using 
[ 14C]dipyridamol monoacetate, as described in sec- 
tion 2. In fig.4, the Scatchard analysis of 
equilibrium is shown. A value of 630000 f 40000 
transporters/cell was obtained and the & was 6.8 
f 0.8 nM; this being very close to the Ki values ob- 
tained from the Dixon plot and the Henderson 
method [ 181. 
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Fig.4. Scatchard analysis of equilibrium of [14C]- 
dipyridamol monoacetate binding to recently isolated 
chromaffln cells. 4 x lo6 cells were incubated in the 
presence of variable concentrations of [‘4C]dipyridamol 
monoacetate (55 mCi/mmol) as described in section 2. 
This figure is the result obtained from 3 different 
experiments in triplicate. 
4. DISCUSSION 
The work reported here shows that adenosine 
transport in recently isolated chromaffin cells can 
be inhibited by a dipyridamol derivative, 
dipyridamol monoacetate, with the same or similar 
effectiveness (Ki = 5 nM) and a non-competitive 
mechanism as described for the non-modified 
compound. In other neural or non-neural cells, 
dipyridamol is also a good inhibitor of adenosine 
transport, although its effectiveness depends on 
the tissue under study [12-14,19-211. It is, 
however, extensively used for clinical purposes, 
essentially in the cardiovascular system. Recently, 
a new adenosine transport inhibitor, nitroben- 
zylthioinosine, has been used to quantify these 
transporters, this presenting a high affinity and 
specificity for some adenosine transporters 
[8,22,23]. It could also prove interesting for later 
comparison of the transporter number obtained 
with these two inhibitors in the same cellular 
model. Dipyridamol monoacetate binding studies 
could furthermore be a tool used to understand the 
pharmacological action of this widely employed 
product. The high-affinity binding sites of 
dipyridamol monoacetate were about 6OOOOO/cell 
which corresponds to 9.5 pmol/mg protein, this 
value being about 70-times greater than that found 
by other authors in whole brain preparations 
employing nitrobenzylthioinosine [22]. This high 
adenosine transporter number could explain the ef- 
fectiveness of these cells to transport adenosine 
[12] in order to (i) replenish the exocytotically 
released ATP [24,25], or (ii) avoid the inhibitory 
effects of adenosine upon secretion in chromaffin 
cells [26]. In chromaffin tissue, ectonucleotidases 
[26,27] can produce adenosine from the ATP 
released. In this way, transport can eliminate the 
inhibitory effects and also ATP recovery via a 
salvage pathway [lo- 121. Nevertheless, we have no 
information at present on the distribution of the 
nucleoside transporters between plasma and inter- 
nal membranes. Perhaps, as occurs with glucose 
transporters, a dynamic equilibrium exists between 
them [28-301, a neural or hormonal control of this 
equilibrium being possible [3 11. Chromaffin cells 
could, thus, be a useful model for a 
neurobiological approach to adenosine action on 
neural tissues and also to evaluate the phar- 
macological action of dipyridamol. 
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